
NewsABC7 News San Francisco (KGO-TV)November 19, 2026San Francisco County
Novo Nordisk clinical trial shows Wegovy reduces BMI in children ages 6 to 11
Photo: ABC7 News San Francisco (KGO-TV)
New clinical trial results show that the weight-loss drug Wegovy reduced Body Mass Index by 10% or more in children ages 6 through 11, prompting the manufacturer to plan an FDA application to lower the approved age. While some doctors view the findings as a promising way to treat childhood obesity and related complications, others raise concerns about common gastrointestinal side effects and potential impacts on linear growth.
Read the full story at ABC7 News San Francisco (KGO-TV)Why It Matters
The findings could lead to the expanded use of medications for children as young as 6, altering treatment options for the approximately one in five U.S. children and adolescents affected by obesity.
Key Facts
- Novo Nordisk shared phase 3 clinical trial results showing Wegovy reduced Body Mass Index by 10% or more among most children with obesity ages 6 through 11.
- After 68 weeks of taking semaglutide, almost 40% of children in the trial no longer had obesity, compared to nearly all patients taking the placebo.
- Novo Nordisk plans to file with the Food and Drug Administration to lower the approved age for Wegovy from 12 years old.
- The World Health Organization recommends against children under 10 receiving pharmacological weight-loss treatments, advising a focus on diet and exercise instead.
- The Centers for Disease Control and Prevention estimates that approximately one in five U.S. children and adolescents have obesity.
- Gastrointestinal side effects were more common in the semaglutide group: vomiting occurred in 70% of participants, diarrhea in 62%, and nausea in 58%.
- Children in the semaglutide group grew about 1.3 inches less in linear growth compared to those in the placebo group during the trial.
Who's Mentioned
OrganizationWorld Health Organization“International public health organization”OrganizationFood and Drug Administration“Federal agency that approves medications for use in the U.S.”OrganizationABC News“News organization that interviewed medical experts”otherWegovy“Weight-loss medication containing semaglutide”PersonDr. Jade Cobern“Pediatrician and preventive medicine specialist”OrganizationHassenfeld Children's Hospital at NYU Langone“Hospital where Dr. Mary Pat Gallagher serves as director of pediatric endocrinol”PersonDr. Mary Pat Gallagher“Director of the division of pediatric endocrinology and diabetes at Hassenfeld C”OrganizationNovo Nordisk“Manufacturer of Wegovy and sponsor of the clinical trial”OrganizationCenters for Disease Control and Prevention“Federal agency tracking health statistics including childhood obesity rates”
